<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Publishing DTD v2.3 20070202//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName journalpublishing.dtd?><?SourceDTD.Version 2.3?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Front Pediatr</journal-id><journal-id journal-id-type="iso-abbrev">Front Pediatr</journal-id><journal-id journal-id-type="publisher-id">Front. Pediatr.</journal-id><journal-title-group><journal-title>Frontiers in Pediatrics</journal-title></journal-title-group><issn pub-type="epub">2296-2360</issn><publisher><publisher-name>Frontiers Media S.A.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">7937974</article-id><article-id pub-id-type="doi">10.3389/fped.2021.618267</article-id><article-categories><subj-group subj-group-type="heading"><subject>Pediatrics</subject><subj-group><subject>Original Research</subject></subj-group></subj-group></article-categories><title-group><article-title>Oxidative Phosphorylation-Mediated E-Selectin Upregulation Is Associated With Endothelia&#x02013;Monocyte Adhesion in Human Coronary Artery Endothelial Cells Treated With Sera From Patients With Kawasaki Disease</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Zhang</surname><given-names>Danfeng</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/853670/overview"/></contrib><contrib contrib-type="author"><name><surname>Liu</surname><given-names>Lingjuan</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/1059245/overview"/></contrib><contrib contrib-type="author"><name><surname>Yuan</surname><given-names>Yuxing</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/1186352/overview"/></contrib><contrib contrib-type="author"><name><surname>Lv</surname><given-names>Tiewei</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/668288/overview"/></contrib><contrib contrib-type="author"><name><surname>Huang</surname><given-names>Xupei</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/33353/overview"/></contrib><contrib contrib-type="author"><name><surname>Tian</surname><given-names>Jie</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="corresp" rid="c001"><sup>*</sup></xref><uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/626400/overview"/></contrib></contrib-group><aff id="aff1"><sup>1</sup><institution>Department of Cardiology, Ministry of Education Key Laboratory of Child Development and Disorders, National Clinical Research Center for Child Health and Disorders, China International Science and Technology Cooperation Base of Child Development and Critical Disorders, Children's Hospital of Chongqing Medical University</institution>, <addr-line>Chongqing</addr-line>, <country>China</country></aff><aff id="aff2"><sup>2</sup><institution>Chongqing Key Laboratory of Pediatrics</institution>, <addr-line>Chongqing</addr-line>, <country>China</country></aff><aff id="aff3"><sup>3</sup><institution>Department of Biomedical Science, Charles E. Schmidt College of Medicine, Florida Atlantic University</institution>, <addr-line>Boca Raton, FL</addr-line>, <country>United States</country></aff><author-notes><fn fn-type="edited-by"><p>Edited by: Oswin Grollmuss, Universit&#x000e9; Paris-Sud, France</p></fn><fn fn-type="edited-by"><p>Reviewed by: Keiichi Hirono, University of Toyama, Japan; Sung-Chou Li, Kaohsiung Chang Gung Memorial Hospital, Taiwan; Xiaoqiong Gu, Guangzhou Medical University, China</p></fn><corresp id="c001">*Correspondence: Jie Tian <email>jietian@cqmu.edu.cn</email></corresp><fn fn-type="other" id="fn001"><p>This article was submitted to Pediatric Cardiology, a section of the journal Frontiers in Pediatrics</p></fn></author-notes><pub-date pub-type="epub"><day>22</day><month>2</month><year>2021</year></pub-date><pub-date pub-type="collection"><year>2021</year></pub-date><volume>9</volume><elocation-id>618267</elocation-id><history><date date-type="received"><day>16</day><month>10</month><year>2020</year></date><date date-type="accepted"><day>19</day><month>1</month><year>2021</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2021 Zhang, Liu, Yuan, Lv, Huang and Tian.</copyright-statement><copyright-year>2021</copyright-year><copyright-holder>Zhang, Liu, Yuan, Lv, Huang and Tian</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p></license></permissions><abstract><p><bold>Background and aims:</bold> E-selectin is a cell adhesion molecule of the vascular endothelium that mediates leukocyte rolling in the early inflammatory responses in many diseases including Kawasaki disease (KD). Previous studies have demonstrated that the expression levels of E-selectin was significantly increased in the sera of KD patients and in endothelial cells of KD patient's autopsy. In this study, we aimed to examine E-selectin levels in endothelial cells treated with sera from KD patients and explore the underlying mechanisms.</p><p><bold>Methods:</bold> Human coronary artery endothelial cells (HCAECs) were randomly incubated with sera from either healthy children [healthy control (HC group)] or pediatric KD patients [assigned as KD with coronary artery lesion (KD-CAL+ group) and KD without coronary artery lesion (KD-CAL&#x02013; group)]. E-selectin levels were determined by RT-qPCR, Western blotting, and immunofluorescence. Cell adhesion assay was performed to quantify the role of E-selectin in intercellular adhesion. High-throughput cell RNA sequencing followed by functional validation was performed to explore the underlying mechanism.</p><p><bold>Results:</bold> E-selectin levels were significantly increased in KD-CAL+ group vs. HC group and KD-CAL&#x02013; group. Compared with the KD-CAL&#x02013; group, endothelia&#x02013;monocyte adhesion was increased in the KD-CAL+ group, while E-selectin-specific siRNA could significantly rescue it. High-throughput cell RNA sequencing analysis also found a significant difference in oxidative phosphorylation (OXPHOS) levels between KD-CAL+ group and KD-CAL&#x02013; group. Functional validation results further confirmed that the OXPHOS was upregulated in the KD-CAL+ group and KD-CAL&#x02013; group compared to that in the HC group, while the KD-CAL+ group exhibited a higher OXPHOS than the KD-CAL&#x02013; group. We also found that the E-selectin levels and endothelia&#x02013;monocyte adhesion were significantly decreased by OXPHOS inhibitor oligomycin in the KD-CAL+ group and KD-CAL&#x02013; group, respectively.</p><p><bold>Conclusion:</bold> Sera from KD patients stimulate OXPHOS levels and enhance E-selectin expression in HCAECs, which may contribute to the development of CAL in KD patients.</p></abstract><kwd-group><kwd>Kawasaki disease</kwd><kwd>coronary artery lesion</kwd><kwd>oxidative phosphorylation</kwd><kwd>E-selectin</kwd><kwd>adhesion molecules</kwd></kwd-group><counts><fig-count count="5"/><table-count count="1"/><equation-count count="0"/><ref-count count="38"/><page-count count="11"/><word-count count="5832"/></counts></article-meta></front><body><sec sec-type="intro" id="s1"><title>Introduction</title><p>Kawasaki disease (KD) is an acute systemic vasculitis that was first described by Tomisaku (<xref rid="B1" ref-type="bibr">1</xref>). The coronary arteries are the most affected vessels (<xref rid="B2" ref-type="bibr">2</xref>), now the leading cause of acquired heart disease in developed countries (<xref rid="B3" ref-type="bibr">3</xref>). The incidence of coronary artery lesion (CAL) varies from regions and races (<xref rid="B4" ref-type="bibr">4</xref>) [19% in the UK (<xref rid="B5" ref-type="bibr">5</xref>), 3.2% in the USA (<xref rid="B6" ref-type="bibr">6</xref>), 3.5% in Canada (<xref rid="B7" ref-type="bibr">7</xref>), 15.9% in Shanghai (<xref rid="B8" ref-type="bibr">8</xref>), and 9.7% in Japan (<xref rid="B9" ref-type="bibr">9</xref>)]. Although the use of intravenous immunoglobulin (IVIG) has been shown to be effective in decreasing the incidence of CAL formation in the acute phase (<xref rid="B10" ref-type="bibr">10</xref>), the pathophysiological mechanism of CAL formation remains unknown. Orenstein et al. (<xref rid="B11" ref-type="bibr">11</xref>) demonstrated three interrelated processes of CAL formation in autopsy specimens from patients who died of KD with cardiovascular events. The studies showed that the infiltration of neutrophils in the vascular wall was stimulated by the damage of endothelial cells at an early stage, resulting in a dysfunction of vascular barrier functions (<xref rid="B11" ref-type="bibr">11</xref>, <xref rid="B12" ref-type="bibr">12</xref>). The infiltration of inflammatory cells depends on adhesion molecules and selectin family, such as intercellular adhesion molecule (ICAM) and E-selectin, etc. (<xref rid="B13" ref-type="bibr">13</xref>).</p><p>Compared with the ICAM-1, E-selectin is a more effective molecule in slowing down leukocyte rolling <italic>in vivo</italic> and <italic>in vitro</italic> (<xref rid="B14" ref-type="bibr">14</xref>), which serves as the only selectin expressed by human endothelial cells during inflammatory stimulation <italic>in vitro</italic> and plays a more significant role in recruiting inflammatory cells in humans (<xref rid="B15" ref-type="bibr">15</xref>). The expression levels of E-selectin can be stimulated by a series of inflammatory molecules including tumor necrosis factor (TNF-&#x003b1;), interleukin-1 (IL-1), or bacterial lipopolysaccharide (LPS). Previous studies showed that E-selectin levels rose to peak after being stimulated by inflammatory cytokines for 4 h then gradually decreased <italic>in vitro</italic> (<xref rid="B16" ref-type="bibr">16</xref>). Moreover, E-selectin has been shown to be involved in rheumatoid arthritis (RA) and atherosclerosis (<xref rid="B16" ref-type="bibr">16</xref>, <xref rid="B17" ref-type="bibr">17</xref>). A previous study found an increment of the soluble form of E-selectin (sE-selectin) in KD patients' sera in the acute phase (<xref rid="B18" ref-type="bibr">18</xref>), and the expression of E-selectin was also observed in the coronary arteries of KD patients with CAL (<xref rid="B19" ref-type="bibr">19</xref>), while a few studies focused on the relationship between E-selectin and inflammatory cell adhesion in CAL formation of KD and the underlying mechanism. Therefore, in the present study, we aimed to examine E-selectin levels in endothelial cells treated with KD patients' sera with or without CAL and explore the underlying mechanism involved in inflammatory cell adhesion of CAL.</p></sec><sec sec-type="methods" id="s2"><title>Methods</title><sec><title>Human Sample Collection</title><p>All subjects were from outpatient and inpatient departments of the Children's Hospital affiliated with Chongqing Medical University. All KD patients met the diagnostic criteria proposed by the Japanese Circulation Society Joint Working Group (JCS) in 2017. The clinical data of the subjects are presented in <xref rid="T1" ref-type="table">Table 1</xref>. The luminal dimensions of the coronary arteries were measured by echocardiography; KD-CAL was defined as Z score &#x0003e;2. During the acute phase, all KD patients were treated with IVIG (2 g/kg) and aspirin (30&#x02013;50 mg/kg/day) initially. IVIG resistance was defined as sustained or recurrent fever (&#x0003e;38&#x000b0;C) at least 36 h after IVIG infusion. Sera from KD patients were collected before IVIG treatment, and sera from healthy children were collected as healthy control (HC). The study was approved by the Medical Research Ethics Committee of the Children's Hospital affiliated with Chongqing Medical University. Written informed consent was obtained from the parents of all subjects. All samples were preserved at &#x02212;80&#x000b0;C.</p><table-wrap id="T1" position="float"><label>Table 1</label><caption><p>Characteristics of healthy controls and KD patients with different coronary artery status.</p></caption><table frame="hsides" rules="groups"><thead><tr style="border-bottom: thin solid #000000;"><th rowspan="1" colspan="1"/><th rowspan="1" colspan="1"/><th valign="top" align="center" colspan="2" rowspan="1"><bold>KD(40)</bold></th><th rowspan="1" colspan="1"/><th rowspan="1" colspan="1"/></tr><tr><th rowspan="1" colspan="1"/><th rowspan="1" colspan="1"/><th valign="top" align="center" rowspan="1" colspan="1"><bold>CAL+</bold></th><th valign="top" align="center" rowspan="1" colspan="1"><bold>CAL-</bold></th><th valign="top" align="center" rowspan="1" colspan="1"><bold>HC</bold></th><th valign="top" align="center" rowspan="1" colspan="1"><bold><xref ref-type="table-fn" rid="TN1"><sup>*</sup></xref></bold><italic><bold>P</bold></italic><bold>-value</bold></th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">Sex</td><td valign="top" align="left" rowspan="1" colspan="1">Male, <italic>n</italic></td><td valign="top" align="center" rowspan="1" colspan="1">13</td><td valign="top" align="center" rowspan="1" colspan="1">12</td><td valign="top" align="center" rowspan="1" colspan="1">7</td><td valign="top" align="center" rowspan="1" colspan="1">0.74</td></tr><tr><td rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Female, <italic>n</italic></td><td valign="top" align="center" rowspan="1" colspan="1">7</td><td valign="top" align="center" rowspan="1" colspan="1">8</td><td valign="top" align="center" rowspan="1" colspan="1">13</td><td rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" colspan="2" rowspan="1">Age, month</td><td valign="top" align="center" rowspan="1" colspan="1">25</td><td valign="top" align="center" rowspan="1" colspan="1">34.4</td><td valign="top" align="center" rowspan="1" colspan="1">58.6</td><td valign="top" align="center" rowspan="1" colspan="1">0.2</td></tr><tr><td valign="top" align="left" colspan="2" rowspan="1">IVIG resistance, <italic>n</italic> (%)</td><td valign="top" align="center" rowspan="1" colspan="1">2 (10%)</td><td valign="top" align="center" rowspan="1" colspan="1">0</td><td valign="top" align="center" rowspan="1" colspan="1">NA</td><td valign="top" align="center" rowspan="1" colspan="1">0.15</td></tr><tr><td valign="top" align="left" colspan="2" rowspan="1">WBC (&#x000d7;10<sup>9</sup>/L), median</td><td valign="top" align="center" rowspan="1" colspan="1">15.3</td><td valign="top" align="center" rowspan="1" colspan="1">13.4</td><td valign="top" align="center" rowspan="1" colspan="1">8.7</td><td valign="top" align="center" rowspan="1" colspan="1">0.11</td></tr><tr><td valign="top" align="left" colspan="2" rowspan="1">PLT (&#x000d7;10<sup>9</sup>/L), median</td><td valign="top" align="center" rowspan="1" colspan="1">401</td><td valign="top" align="center" rowspan="1" colspan="1">396</td><td valign="top" align="center" rowspan="1" colspan="1">307</td><td valign="top" align="center" rowspan="1" colspan="1">0.26</td></tr><tr><td valign="top" align="left" colspan="2" rowspan="1">HB (g/L), median</td><td valign="top" align="center" rowspan="1" colspan="1">98</td><td valign="top" align="center" rowspan="1" colspan="1">106</td><td valign="top" align="center" rowspan="1" colspan="1">113</td><td valign="top" align="center" rowspan="1" colspan="1">0.97</td></tr><tr><td valign="top" align="left" colspan="2" rowspan="1">CRP (mg/L), median</td><td valign="top" align="center" rowspan="1" colspan="1">45</td><td valign="top" align="center" rowspan="1" colspan="1">37</td><td valign="top" align="center" rowspan="1" colspan="1">NA</td><td valign="top" align="center" rowspan="1" colspan="1">0.64</td></tr><tr><td valign="top" align="left" colspan="2" rowspan="1">ESR (mm/h), median</td><td valign="top" align="center" rowspan="1" colspan="1">74</td><td valign="top" align="center" rowspan="1" colspan="1">56</td><td valign="top" align="center" rowspan="1" colspan="1">NA</td><td valign="top" align="center" rowspan="1" colspan="1">0.73</td></tr></tbody></table><table-wrap-foot><fn id="TN1"><label>*</label><p><italic>P-values were calculated by Man-Whitney U test for continuous variables and chi square test for categorical variables between CAL+ and CAL&#x02013; group. KD, Kawasaki disease; CAL, coronary artery lesion; IVIG, intravenous immunoglobulin; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; WBC, white blood cell count; NA, not applicable</italic>.</p></fn></table-wrap-foot></table-wrap></sec><sec><title>Cell Culture</title><p>Human coronary artery endothelial cells (HCAECs) were cultured in Dulbecco's modified Eagle's medium (DMEM)/F12, supplemented with 10% fetal bovine serum (FBS), 50 units/ml penicillin, and streptomycin at 37&#x000b0;C in 5% CO<sub>2</sub>. Before performing subsequent experiments, cells were treated with DMEM/F12 supplemented with 15% sera from KD patients or HC for 4 h. THP-1 cells were cultured in RPMI-1640, supplemented with 10% FBS, 50 units/ml penicillin, and streptomycin at 37&#x000b0;C in 5% CO<sub>2</sub>. Cells at passages 4&#x02013;6 were used for the following experiments <italic>in vitro</italic>.</p></sec><sec><title>Total RNA/DNA Isolation and Quantitative Real-Time PCR Analysis</title><p>Total RNA was extracted with TRIzol reagent (Sigma). RNA purity and concentration were determined by measuring the absorbances at 260 and 280 nm, respectively. PrimeScript&#x02122; RT reagent kit (TaKaRa) was used to obtain complementary DNA (cDNA). The total genomic DNA was extracted with the animal tissue/cell genomic DNA extraction Kit (Solarbio). qPCR reactions in the presence of SYBR Green were performed on CFX 96&#x02122; Real-Time System (BIO-RAD). The primer sequences for qPCR were as follows: sele-For: <italic>5</italic>&#x02032; &#x02212; <italic>GCCTGCAATGTGGTTGAGTG</italic> &#x02212; 3&#x02032; and sele-Rev: <italic>5</italic>&#x02032; &#x02212; <italic>GCACCTCACAGAGCCATTCT</italic> &#x02212; 3&#x02032;<italic>;</italic> GAPDH-For: <italic>5</italic>&#x02032; &#x02212; <italic>GTCTCCTCTGACTTCAACAGCG</italic> &#x02212; 3&#x02032; and GAPDH-Rev: <italic>ACCACCCTGTTGCTGTAGCCAA-3</italic>&#x02032;<italic>;</italic> mtDNA-For: <italic>5</italic>&#x02032; &#x02212; <italic>GGGGAAGCAGATTTGGGTAC</italic> &#x02212; 3&#x02032; and mtDNA-Rev: <italic>5</italic>&#x02032; &#x02212; <italic>AGGGTGGGTAGGTTTGTTGG</italic> &#x02212; 3&#x02032;<italic>;</italic> 18SRNA-For: <italic>5</italic>&#x02032; &#x02212; <italic>CAGGAAGGAAGGCTGGAAG</italic> &#x02212; 3&#x02032; and 18SRNA-Rev: <italic>5</italic>&#x02032; &#x02212; <italic>CGGGAAATCGTGCGTGAC</italic> &#x02212; 3&#x02032;. The relative expression was calculated using the 2<sup>&#x02212;&#x00394;&#x00394;Ct</sup> method.</p></sec><sec><title>High-Throughput RNA Sequencing</title><p>Preparation of cDNA libraries and Illumina novaseq 6000 RNA sequencing were performed at Novogene Co., LTD (Beijing, China). Differential expression analysis of HCAECs incubated with serum from acute KD patients with CAL (KD-CAL+, <italic>n</italic> = 3) or KD without CAL (KD-CAL&#x02013;, <italic>n</italic> = 3) was performed using the DESeq2 R package (1.16.1). DESeq2 provides statistical routines for determining differential expression in digital gene expression data using a model based on the negative binomial distribution. Genes with a <italic>P</italic>-value &#x0003c;0.05 found by DESeq2 were assigned as differentially expressed.</p><p>Gene Ontology (GO) enrichment analysis of differentially expressed genes was implemented by the Cluster Profiler R package, in which gene length bias was corrected. GO terms with corrected <italic>P</italic>-value &#x0003c;0.05 were considered significantly enriched by differentially expressed genes.</p><p>The Cluster Profiler R package was used to test the statistical enrichment of differential expression genes in Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways.</p></sec><sec><title>Western Blotting Assays</title><p>Total fresh protein extracts were isolated from HCAECs using enhanced radioimmunoprecipitation assay (RIPA) lysis buffer (Beyotime) supplemented with protease and phosphatase inhibitors (Roche). Pierce BCA Protein Assay Kit (Thermo) was used for protein quantification. Equal protein samples (30&#x02013;100 &#x003bc;g) were separated on 10% sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis (PAGE) gels. The following primary antibodies were used: rabbit anti-E-selectin (1:500 dilutions, CST, Danvers, USA), mouse anti-GAPDH (1:1,000 dilutions, OriGene, Beijing, China). Horseradish peroxidase-coupled secondary antibodies (1:5,000 dilutions, Proteintech, Wuhan, China) were used to detect primary antibody binding.</p></sec><sec><title>Immunofluorescence Assays</title><p>HCAECs were fixed with 4% paraformaldehyde and sealed with bovine serum albumin (BSA). Fluorescein isothiocyanate (FITC)-labeled goat anti-rabbit IgG (H+L) secondary antibody (1:500 dilutions, Beyotime) was used to detect rabbit anti-E-selectin (1:200 dilutions, CST, Danvers, USA). Dil (Beyotime) was used for cell membrane labeling. Here, 4&#x02032;,6-diamidino-2-phenylindole (DAPI; Keygen) was used for nucleus labeling. Fluorescence was measured by confocal microscopy. The NIS Element Viewer statistical software was used to calculate the fluorescence intensity.</p></sec><sec><title>Endothelia-Monocyte Adhesion Assay</title><p>The HCAECs were seeded into 12-well plates, cultured to 100% fusion. THP-1 cells were incubated for 30 min at 37&#x000b0;C labeled with 2&#x02032;,7&#x02032;-bis-(2-carboxyethyl)-5-(and-6)-carboxyfluorescein acetoxymethyl ester (BCECF-AM). The fluorescently labeled THP-1 (1 &#x000d7; 10<sup>5</sup>/well) cells were added into HCAECs, then incubated at 37&#x000b0;C for 1 h. Suspended THP-1 cells were removed with Hank's balanced salt solution with HEPES buffer (HHBS), cell lysis buffer was added, and scraped. The images were collected under a fluorescence microscope. The fluorescence intensity was measured at microplate reader excitation and emission wavelengths of 490 and 530 nm, respectively.</p></sec><sec><title>Measurement of ATP Content in Cells</title><p>ATP Assay Kit (Beyotime) was used to measure the content of ATP in HCAECs. Samples were prepared according to the instructions. The measurements were made with a chemiluminescence apparatus.</p></sec><sec><title>Assessment of Mitochondrial Membrane Potential</title><p>Mitochondrial membrane potential assay kit with JC-1 fluorescent probe (Beyotime) was used to measure the mitochondrial membrane potential. Fluorescence was measured by confocal microscopy.</p></sec><sec><title>Assessment of Mitochondrial Respiratory Chain Complex I Activity</title><p>Mitochondrial complex I activity detection assay kit (Solarbio) was used to measure the mitochondrial respiratory chain complex I activity. The absorbance was measured at 340 nm with a microplate reader. Record absorbance A1 at 10 s, reaction at 37&#x000b0;C for 2 min, record absorbance A2 at 2 min, calculate &#x00394;A = A1&#x02013;A2. Pierce BCA Protein Assay Kit (Thermo) was used for protein quantification. Complex I activity (U/mg prot) = [&#x00394;<italic>A</italic>&#x000d7;<italic>Vtotal</italic>&#x000f7;(&#x003b5;&#x000d7; <italic>d</italic>) &#x000d7;10<sup>9</sup>] &#x000f7; (Vsample &#x000d7; Cpr) &#x000f7; T = 2,679.5 &#x000d7; &#x00394;A &#x000f7; Cpr (Vtotal = 2 &#x000d7; 10<sup>&#x02212;4</sup> L; &#x003b5;: NADH molar extinction coefficient, 6.22 &#x000d7; 10<sup>3</sup> L/mol/cm; d: 96-well plates diameter, 0.6 cm; Vsample = 0.01 ml; T: Reaction time, 2 min; Cpr: Sample protein concentration, mg/ml).</p></sec><sec><title>Statistical Analysis</title><p>All values were expressed as means &#x000b1; SEM. Mann&#x02013;Whitney U test or ANOVA followed by the Bonferroni <italic>post-hoc</italic> test was used to analyze differences among groups. <italic>P</italic> &#x0003c; 0.05 was considered statistically significant.</p></sec></sec><sec sec-type="results" id="s3"><title>Results</title><sec><title>Kawasaki Disease Sera Increased E-Selectin Level in Human Coronary Artery Endothelial Cells</title><p>We first detected the levels of E-selectin in HCAECs after treatment with KD sera or healthy control sera for 4 h. As shown in <xref ref-type="fig" rid="F1">Figures 1A&#x02013;C</xref>, incubation of HCAECs with sera from KD subjects with CAL+ resulted in a significantly higher expression of E-selectin when compared with CAL&#x02013; and HC group, which followed the order of HC &#x0003c; KD-CAL&#x02013; &#x0003c;KD-CAL+. Intracellular localization and the expression levels of E-selectin were determined by immunofluorescence. As shown in <xref ref-type="fig" rid="F1">Figures 1D,E</xref>, E-selectin was mainly distributed in the cell membrane and cytoplasm when treated with serum from KD subjects. The expression levels of E-selectin were consistent with Western blot and qPCR.</p><fig id="F1" position="float"><label>Figure 1</label><caption><p>Kawasaki disease (KD) sera increased E-selectin level in human coronary artery endothelial cells (HCAECs). <bold>(A&#x02013;C)</bold> HCAECs were treated with medium containing 15% sera from healthy controls (HCs; <italic>n</italic> = 6), KD without coronary artery lesion (KD-CAL&#x02013;; <italic>n</italic> = 6), and KD with coronary artery lesion (KD-CAL+; <italic>n</italic> = 6) for 4 h. The E-selectin mRNA levels were measured by qPCR (<bold>A</bold>, HC = 6, KD-CAL&#x02013; = 6, KD-CAL+ = 6), and protein levels were measured by Western blot (<bold>B</bold>, HC = 6, KD-CAL&#x02013; = 6, KD-CAL+ = 6). <bold>(C)</bold> Statistical analysis of immunoblots. <bold>(D,E)</bold> HCAECs were treated with medium containing 15% sera from HCs (<italic>n</italic> = 6), KD-CAL&#x02013; (<italic>n</italic> = 6), and KD-CAL+ (<italic>n</italic> = 6) for 4 h; localization and expression of E-selectin (green) in HCAECs were measured by immunofluorescence. <bold>(D,E)</bold> Statistical analysis of immunofluorescence. The bar graphs are mean &#x000b1; SEM. <sup>**</sup><italic>P</italic> &#x0003c; 0.01 compared with the indicated group.</p></caption><graphic xlink:href="fped-09-618267-g0001"/></fig></sec><sec><title>E-Selectin Was Involved in Kawasaki Disease Endothelia&#x02013;Monocyte Interaction</title><p>To investigate the role of E-selectin in endothelia&#x02013;monocyte interactions in KD, we performed cell adhesion assays. HCAECs were pretreated with specific siRNA of E-selectin (sense: 5&#x02032;-GGUUGAAUGCACCACUCAATT-3&#x02032; and antisense: 5&#x02032;-UUGAGUGGUGCAUUCAACCTT-3&#x02032;) or negative control siRNA (sense: 5&#x02032;-UUCUCCGAACGUGUCACGUTT-3&#x02032; and antisense: 5&#x02032;-ACGUGACACGUUCGGAGAATT-3&#x02032;) for 72 h before culturing with sera of KD subjects with CAL or without CAL for another 4 h, incubating with BCECF-AM-labeled THP-1 cells for 1 h. As shown in <xref ref-type="fig" rid="F2">Figures 2A&#x02013;C</xref>, the adhesion of THP-1 cells was significantly increased in the CAL+ group compared with the CAL&#x02013; group, while this process was significantly rescued by siRNA of E-selectin.</p><fig id="F2" position="float"><label>Figure 2</label><caption><p>E-selectin was involved in Kawasaki disease (KD) endothelia&#x02013;monocyte interactions. Human coronary artery endothelial cells (HCAECs) were treated with specific E-selectin siRNA (100 nM) or negative control siRNA (100 nM) for 72 h, followed by medium containing 15% sera from KD-CAL&#x02013; (<italic>n</italic> = 6) and KD-CAL+ (<italic>n</italic> = 6) subjects for 4 h. Changed the medium to Hank's balanced salt solution with HEPES buffer (HHBS) and incubated with 2&#x02032;,7&#x02032;-bis-(2-carboxyethyl)-5-(and-6)-carboxyfluorescein acetoxymethyl ester (BCECF-AM)-labeled THP-1 cells for 1 h, then the suspended cells were washed with phosphate buffered saline (PBS). <bold>(A)</bold> The effects of siRNA (pooled from three KD subjects). <bold>(B)</bold> Representative images used quantification of THP-1 cells (green, BCECF-AM) attached to human umbilical vein endothelial cells (HUVECs). <bold>(C)</bold> Quantitative analysis of adherent THP-1 cells lysate fluorescence at 490-nm excitation and 530-nm emission. All samples were normalized to HCAECs with CAL serum treatment. The bar graphs are mean &#x000b1; SEM. <sup>**</sup><italic>P</italic> &#x0003c; 0.01 compared with the indicated group.</p></caption><graphic xlink:href="fped-09-618267-g0002"/></fig></sec><sec><title>Upregulation of Oxidative Phosphorylation in Human Coronary Artery Endothelial Cells Treated With Kawasaki Disease With Coronary Artery Lesion Sera</title><p>To investigate the underlying mechanism of E-selectin upregulation in KD sera-treated HCAECs, high-throughput RNA sequencing of HCAECs was conducted, which were treated by sera from acute KD patients with or without CAL for 4 h. After that, the differential gene analysis including GO and KEGG enrichment analysis of differentially expressed genes was performed (PRJNA686838). As shown in <xref ref-type="fig" rid="F3">Figures 3A,B</xref>, there were 767 genes upregulated and 765 genes downregulated compared with those of the KD-CAL- group. As shown in <xref ref-type="fig" rid="F3">Figures 3C,D</xref>, genes associated with oxidative phosphorylation (OXPHOS) (<xref ref-type="supplementary-material" rid="SM1">Supplementary Table 1</xref>) and ATP metabolism (<xref ref-type="supplementary-material" rid="SM1">Supplementary Table 2</xref>) were significantly upregulated. Pathways associated with OXPHOS were significantly upregulated. To confirm the upregulated OXPHOS process, we first examined the ATP level of HCAECs treated with KD and HC sera because OXPHOS is the main way of ATP production. As shown in <xref ref-type="fig" rid="F4">Figure 4B</xref>, HCAECs treated with sera from KD-CAL+ showed a high level of ATP content when compared to that of the KD-CAL&#x02013; group and HC group. But previous studies have indicated that the main source of ATP in HCAECs was glycolysis, not OXPHOS (<xref rid="B20" ref-type="bibr">20</xref>). We also found that the ATP was significantly decreased in HCAECs after intervention with deoxyglucose (10 mM) for 12 h than that after oligomycin (50 &#x003bc;g/ml) (<xref ref-type="fig" rid="F4">Figure 4A</xref>). To determine whether the increased ATP content was due to the upregulation of OXPHOS, mitochondrial membrane potential, mitochondrial gene transcription level, and mitochondrial complex I activity were tested. As shown in <xref ref-type="fig" rid="F4">Figures 4C&#x02013;F</xref>, HCAECs treated with serum from KD-CAL+ showed a high level of mitochondrial membrane potential, mitochondrial gene transcription level, and mitochondrial complex I activity compared with those of the KD-CAL&#x02013; group and HC group.</p><fig id="F3" position="float"><label>Figure 3</label><caption><p>High-throughput RNA sequencing of Kawasaki disease (KD) sera-treated human coronary artery endothelial cells (HCAECs). HCAECs were treated with medium containing 15% sera from KD with coronary artery lesion (KD-CAL+; <italic>n</italic> = 3; group A) or KD without coronary artery lesion (KD-CAL&#x02013;; <italic>n</italic> = 3; group B) for 4 h. The total RNA was isolated to perform Illumina novaseq 6000 RNA sequencing. <bold>(A)</bold> Differential expression gene clustering heat map. The abscissa is the sample name, and the ordinate is the normalized value of the differentially expressed gene FPKM. The redder the color, the higher the expression; the greener, the lower the expression. <bold>(B)</bold> Differential gene volcano-gram. The abscissa is log2FoldChange value, and the ordinate is &#x02013;log10 padj or &#x02013;log10 <italic>p</italic>-value. The blue dotted line represents the threshold line of the differential gene screening criteria. <bold>(C)</bold> Gene Ontology (GO) enrichment analysis bubble chart. The ordinate is GO Term, abscissa for the GO Term enrichment significant. <bold>(D)</bold> Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analysis bubble chart. The ordinate is the KEGG pathway, and the abscissa is the significance level of the enrichment of the pathway.</p></caption><graphic xlink:href="fped-09-618267-g0003"/></fig><fig id="F4" position="float"><label>Figure 4</label><caption><p>Increased oxidative phosphorylation in Kawasaki disease with coronary artery lesion (KD-CAL+) sera-treated human coronary artery endothelial cells (HCAECs). <bold>(A)</bold> HCAECs were treated with deoxyglucose (50 &#x003bc;g/ml) and oligomycin (10 mM) for 12 h. Intracellular ATP content was determined by chemiluminescence apparatus. <bold>(B)</bold> HCAECs were treated with medium containing 15% sera from healthy controls (HCs; <italic>n</italic> = 6), Kawasaki disease without coronary artery lesion (KD-CAL&#x02013;; <italic>n</italic> = 6), and KD-CAL+ (<italic>n</italic> = 6) for 4 h. Intracellular ATP content was determined by chemiluminescence apparatus. <bold>(C)</bold> HCAECs were treated with medium containing 15% serum from HC (<italic>n</italic> = 6), KD-CAL&#x02013; (<italic>n</italic> = 6), and KD-CAL+ (<italic>n</italic> = 6) for 4 h. Mitochondrial Complex I activity was determined in 340 nm with a microplate reader. <bold>(D)</bold> HCAECs were treated with medium containing 15% sera from HC (<italic>n</italic> = 6), KD-CAL&#x02013; (<italic>n</italic> = 6), and KD-CAL+ (<italic>n</italic> = 6) for 4 h. Mitochondrial gene copy number was measured by qPCR. <bold>(E,F)</bold> HCAECs were treated with medium containing 15% sera from HC (<italic>n</italic> = 6), KD-CAL&#x02013; (<italic>n</italic> = 6), and KD-CAL+ (<italic>n</italic> = 6) for 4 h. Mitochondrial membrane potential was determined by JC-1 (monomers green, aggregates red) analyzed by confocal microscopy. <bold>(F)</bold> Statistical analysis of relative fluorescence intensity (red/green). All samples were normalized to HCAECs with CAL serum treatment or control. The bar graphs are mean &#x000b1; SEM. <sup>*</sup><italic>P</italic> &#x0003c; 0.05 and <sup>**</sup><italic>P</italic> &#x0003c; 0.01 compared with the indicated group.</p></caption><graphic xlink:href="fped-09-618267-g0004"/></fig></sec><sec><title>Oxidative Phosphorylation Was Involved in the Expression of E-Selectin and Endothelia&#x02013;Monocyte Interaction</title><p>To explore the role of OXPHOS in the expression of E-selectin, oligomycin (50 &#x003bc;g/ml), a phosphorylation-specific inhibitor, or DMSO was added when HCAECs were treated with sera from KD patients with different coronary artery outcomes for 4 h. As shown, the expression levels of E-selectin mRNA and protein were significantly decreased after treated with oligomycin (<xref ref-type="fig" rid="F5">Figures 5A&#x02013;C</xref>). To examine the role of OXPHOS on intercellular adhesion, HCAECs were treated with sera from KD patients with different coronary artery outcomes with oligomycin (50 &#x003bc;g/ml) or DMSO for 4 h, then incubated with BCECF-AM-labeled THP-1 for another 1 h, and the adherent THP-1 cells were measured with a microplate reader. Cell adhesion was significantly reduced when treated with oligomycin (<xref ref-type="fig" rid="F5">Figures 5D,E</xref>).</p><fig id="F5" position="float"><label>Figure 5</label><caption><p>Oxidative phosphorylation was involved in the expression of E-selectin and monocyte&#x02013;endothelial cell interaction. <bold>(A&#x02013;E)</bold> Human coronary artery endothelial cells (HCAECs) were treated with medium containing 15% sera from Kawasaki disease without coronary artery lesion (KD-CAL&#x02013;; <italic>n</italic> = 6) and Kawasaki disease with coronary artery lesion (KD-CAL+; <italic>n</italic> = 6) subjects plus oligomycin (50 &#x003bc;g/ml) or DMSO (same volume) for 4 h. The E-selectin mRNA levels were measured by qPCR <bold>(A)</bold>, and protein levels were measured by Western blot <bold>(B)</bold>. <bold>(C)</bold> Statistical analysis of immunoblots. <bold>(E)</bold> HCAECs were treated with medium containing 15% sera from KD-CAL&#x02013; (<italic>n</italic> = 6) and KD-CAL+ (<italic>n</italic> = 6) subjects plus oligomycin (50 &#x003bc;g/ml) or DMSO (same volume) for 4 h then co-incubated with 2&#x02032;,7&#x02032;-bis-(2-carboxyethyl)-5-(and-6)-carboxyfluorescein acetoxymethyl ester (BCECF-AM)-labeled THP-1 cells for 1 h. Representative images used quantification of THP-1 cells (green) attached to human umbilical vein endothelial cells (HUVECs). <bold>(D)</bold> Quantitative analysis of adherent THP-1 cells lysate fluorescence at 490-nm excitation and 530-nm emission. All samples were normalized to HCAECs with CAL serum treatment. The bar graphs are mean &#x000b1; SEM. <sup>**</sup><italic>P</italic> &#x0003c; 0.01 compared with the indicated group.</p></caption><graphic xlink:href="fped-09-618267-g0005"/></fig></sec></sec><sec sec-type="discussion" id="s4"><title>Discussion</title><p>The main finding of this study is that the upregulation of E-selectin was related to the endothelia&#x02013;monocyte interaction in KD sera-treated HCAECs, which may be one of the mechanisms of CAL formation. The upregulation of ATP production and mitochondrial OXPHOS may be the underlying mechanism.</p><p>E-selectin serves as an important link between endothelial cells and inflammatory cells. Elevated cellular E-selectin can be seen in some chronic inflammatory diseases, such as diabetes, atherosclerosis, and obesity (<xref rid="B21" ref-type="bibr">21</xref>&#x02013;<xref rid="B23" ref-type="bibr">23</xref>). A previous study reported that the concentration of sE-selectin is directly correlated with cell surface expression (<xref rid="B24" ref-type="bibr">24</xref>). Due to the elevated expression of sE-selectin in KD patients (<xref rid="B18" ref-type="bibr">18</xref>), we hypothesized that E-selectin may be involved in the KD CAL process. In the present study, we found that KD-CAL+ sera-treated HCAECs exhibited a higher mRNA level and protein level of E-selectin when compared with KD-CAL&#x02013; group and HC control. The levels of E-selectin were increased in RNA level in this study, and the increase in protein levels were consistent with the change in RNA level, basically excluding the possible false positive caused by sE-selectin in sera. E-selectin is mainly involved in the adhesion process of inflammatory cells; we found that the adherent THP-1 cells of the KD-CAL+ sera-treated HCAECs were significantly increased, which may lead to more severe inflammatory cell infiltration compared to that in the KD-CAL&#x02013; group. The results indicated that a higher concentration of E-selectin may lead to more serious endothelia&#x02013;monocyte interaction, which may be related to CAL formation, while ICAM and other molecules might be involved as well. To confirm the role of E-selectin in the adhesion process, we used specific E-selectin siRNA to silence the expression of E-selectin. As a result, the adhesion number of THP-1 cells was significantly decreased compared with negative control siRNA, indicating that the lack of the E-selectin may reduce the endothelia&#x02013;monocyte interaction, which may be involved in the formation of CAL.</p><p>Rowley's team performed RNA sequencing using the coronary artery tissue of KD with KD-CAL (<xref rid="B25" ref-type="bibr">25</xref>). The results showed that T lymphocyte activation, antigen presentation and dendritic cell function, immunoglobulin production, and type I interferon response were the main significantly upregulated molecular pathways. However, in this study, the OXPHOS was significantly upregulated. The differences between the two studies may be complicated. Firstly, sources of samples are different, Rowley's study examined the total human coronary artery, the cell types are various, while the present study mainly focused on HCAECs and just <italic>in vitro</italic>. Secondly, we compared the differences between the KD-CAL+ group, KD-CAL&#x02013; group, and HC group, while Rowley's study only focused on the KD-CAL+ group and HC group. Moreover, Rowley's study focused on the subacute or chronic stage of CAL, while the present study mainly focused on the acute stage. Although different conclusions have been drawn, all of them could be the potential molecular biological mechanism of KD CAL formation.</p><p>Mitochondria are the sites of OXPHOS involved in the regulation of inflammatory stimulating in many diseases (<xref rid="B26" ref-type="bibr">26</xref>&#x02013;<xref rid="B28" ref-type="bibr">28</xref>). ATP in endothelial cells is mostly provided by glycolysis rather than OXPHOS (<xref rid="B20" ref-type="bibr">20</xref>, <xref rid="B29" ref-type="bibr">29</xref>). As a result, the function of OXPHOS is neglected. Mitochondria play a role in endothelial inflammatory stimulation mainly by regulating the production of nitric oxide (NO) (<xref rid="B30" ref-type="bibr">30</xref>) and reactive oxygen species (ROS) (<xref rid="B31" ref-type="bibr">31</xref>), as well as the dynamics of intracellular [Ca<sup>2+</sup>] signaling (<xref rid="B32" ref-type="bibr">32</xref>). A previous study showed that ROS production plays an important role in coronary dysfunction in KD (<xref rid="B33" ref-type="bibr">33</xref>). In our study, the OXPHOS in HCAECs was stimulated by KD sera compared with HC sera, accompanied by the increment in the CAL+ group compared with the CAL&#x02013; group, indicating that there may be a large number of ROS produced. A previous study reported that OXPHOS can regulate nuclear factor (NF)-&#x003ba;b signaling pathway in tumor necrosis factor (TNF)-&#x003b1;-stimulated endothelial inflammation (<xref rid="B34" ref-type="bibr">34</xref>). The expression of E-selectin is mainly dependent on the NF-&#x003ba;b signal pathway (<xref rid="B35" ref-type="bibr">35</xref>). In a previous study, OXPHOS uncouplers can reduce the expression of adhesion molecules through the NF-&#x003ba;B signaling pathway both <italic>in vitro</italic> and <italic>in vivo</italic> (<xref rid="B36" ref-type="bibr">36</xref>, <xref rid="B37" ref-type="bibr">37</xref>). NF-&#x003ba;b signaling pathway is important in KD, IVIG can significantly inhibit the activation of NF-&#x003ba;b signaling pathway to reducing the incidence of CAL (<xref rid="B38" ref-type="bibr">38</xref>). In the present study, OXPHOS inhibitor can alleviate the expression of E-selectin, suggesting that the reduction of the ROS production and NF-&#x003ba;b pathway may be involved in the underlying mechanism of protecting endothelia from inflammation.</p><p>The limitation of this study is that we did not further explore the advancing mechanisms of how OXPHOS affects E-selectin expression and which specific factors in sera affect the expression of E-selectin. We also lack <italic>in vivo</italic> data to support our conclusions. Although freshly harvested endothelial cells isolated from the coronary arteries can most intuitively reflect the changes of the cell functions in patients during the development of KD, a measurement of <italic>Lactobacillus casei</italic> cell wall extract (LCWE)-induced mouse models in exploring the effects of E-selectin and OXPHOS pathway on vasculitis may warrant further studies.</p><p>In conclusion, the E-selectin and OXPHOS pathway reported in this study may be important factors involved in endothelia&#x02013;monocyte interaction of CAL development in KD patients and may be useful clues as potential targets in the treatment of the disease. Further <italic>in vivo</italic> experiments are needed to confirm the conclusion.</p></sec><sec sec-type="data-availability" id="s5"><title>Data Availability Statement</title><p>The datasets presented in this study can be found in the NCBI SRA database, accession number: ID:<ext-link ext-link-type="NCBI:sra" xlink:href="PRJNA686838">PRJNA686838</ext-link>.</p></sec><sec id="s6"><title>Author Contributions</title><p>DZ contributed to conception, methodology, research conducte, data curation, and wrote the first draft of the manuscript. All authors contributed to manuscript revision, read, and approved the submitted version.</p></sec><sec sec-type="COI-statement" id="conf1"><title>Conflict of Interest</title><p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p></sec></body><back><sec sec-type="supplementary-material" id="s7"><title>Supplementary Material</title><p>The Supplementary Material for this article can be found online at: <ext-link ext-link-type="uri" xlink:href="https://www.frontiersin.org/articles/10.3389/fped.2021.618267/full#supplementary-material">https://www.frontiersin.org/articles/10.3389/fped.2021.618267/full#supplementary-material</ext-link></p><supplementary-material content-type="local-data" id="SM1"><media xlink:href="Table_1.DOCX"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec><ref-list><title>References</title><ref id="B1"><label>1.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kawasaki</surname><given-names>T</given-names></name></person-group>. <article-title>Acute febrile mucocutaneous syndrome with lymphoid involvement with specific desquamation of the fingers and toes in children</article-title>. <source>Arerugi</source>. (<year>1967</year>) <volume>16</volume>:<fpage>178</fpage>&#x02013;<lpage>222</lpage>. <?supplied-pmid 6062087?><pub-id pub-id-type="pmid">6062087</pub-id></mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yonesaka</surname><given-names>S</given-names></name><name><surname>Takahashi</surname><given-names>T</given-names></name><name><surname>Eto</surname><given-names>S</given-names></name><name><surname>Sato</surname><given-names>T</given-names></name><name><surname>Otani</surname><given-names>K</given-names></name><name><surname>Ueda</surname><given-names>T</given-names></name><etal/></person-group>. <article-title>Biopsy-proven myocardial sequels in Kawasaki disease with giant coronary aneurysms</article-title>. <source>Cardiol Young</source>. (<year>2010</year>) <volume>20</volume>:<fpage>602</fpage>&#x02013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1017/S1047951109991132</pub-id><pub-id pub-id-type="pmid">20584347</pub-id></mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Newburger</surname><given-names>JW</given-names></name><name><surname>Takahashi</surname><given-names>M</given-names></name><name><surname>Gerber</surname><given-names>MA</given-names></name><name><surname>Gewitz</surname><given-names>MH</given-names></name><name><surname>Tani</surname><given-names>LY</given-names></name><name><surname>Burns</surname><given-names>JC</given-names></name><etal/></person-group>. <article-title>Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association</article-title>. <source>Circulation</source>. (<year>2004</year>) <volume>110</volume>:<fpage>2747</fpage>&#x02013;<lpage>71</lpage>. <pub-id pub-id-type="doi">10.1161/01.CIR.0000145143.19711.78</pub-id><pub-id pub-id-type="pmid">15505111</pub-id></mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lue</surname><given-names>HC</given-names></name><name><surname>Chen</surname><given-names>LR</given-names></name><name><surname>Lin</surname><given-names>MT</given-names></name><name><surname>Chang</surname><given-names>LY</given-names></name><name><surname>Wang</surname><given-names>JK</given-names></name><name><surname>Lee</surname><given-names>CY</given-names></name><etal/></person-group>. <article-title>Epidemiological features of Kawasaki disease in Taiwan, 1976&#x02013;2007: results of five nationwide questionnaire hospital surveys</article-title>. <source>Pediatr Neonatol</source>. (<year>2014</year>) <volume>55</volume>:<fpage>92</fpage>&#x02013;<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1016/j.pedneo.2013.07.010</pub-id><?supplied-pmid 24120536?><pub-id pub-id-type="pmid">24120536</pub-id></mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tulloh</surname><given-names>R</given-names></name><name><surname>Mayon-White</surname><given-names>R</given-names></name><name><surname>Harnden</surname><given-names>A</given-names></name><name><surname>Ramanan</surname><given-names>AV</given-names></name><name><surname>Tizard</surname><given-names>EJ</given-names></name><name><surname>Shingadia</surname><given-names>D</given-names></name><etal/></person-group>. <article-title>Kawasaki disease: a prospective population survey in the UK and Ireland from 2013 to 2015</article-title>. <source>Archiv Dis Childhood</source>. (<year>2019</year>) <volume>104</volume>:<fpage>640</fpage>&#x02013;<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1136/archdischild-2018-315087</pub-id><?supplied-pmid 32079592?><pub-id pub-id-type="pmid">32079592</pub-id></mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Okubo</surname><given-names>Y</given-names></name><name><surname>Nochioka</surname><given-names>K</given-names></name><name><surname>Sakakibara</surname><given-names>H</given-names></name><name><surname>Testa</surname><given-names>M</given-names></name><name><surname>Sundel</surname><given-names>RP</given-names></name></person-group>. <article-title>National survey of pediatric hospitalizations due to Kawasaki disease and coronary artery aneurysms in the USA</article-title>. <source>Clin Rheumatol</source>. (<year>2017</year>) <volume>36</volume>:<fpage>413</fpage>&#x02013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1007/s10067-016-3512-6</pub-id><?supplied-pmid 27987089?><pub-id pub-id-type="pmid">27987089</pub-id></mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Manlhiot</surname><given-names>C</given-names></name><name><surname>O'Shea</surname><given-names>S</given-names></name><name><surname>Bernknopf</surname><given-names>B</given-names></name><name><surname>LaBelle</surname><given-names>M</given-names></name><name><surname>Chahal</surname><given-names>N</given-names></name><name><surname>Dillenburg</surname><given-names>RF</given-names></name><etal/></person-group>. <article-title>Epidemiology of Kawasaki disease in Canada 2004 to 2014: comparison of surveillance using administrative data vs periodic medical record review</article-title>. <source>Can J Cardiol</source>. (<year>2018</year>) <volume>34</volume>:<fpage>303</fpage>&#x02013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1016/j.cjca.2017.12.009</pub-id><?supplied-pmid 29395706?><pub-id pub-id-type="pmid">29395706</pub-id></mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>JJ</given-names></name><name><surname>Ma</surname><given-names>XJ</given-names></name><name><surname>Liu</surname><given-names>F</given-names></name><name><surname>Yan</surname><given-names>WL</given-names></name><name><surname>Huang</surname><given-names>MR</given-names></name><name><surname>Huang</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Epidemiologic features of Kawasaki disease in Shanghai from 2008 through 2012</article-title>. <source>Pediatr Infect Dis J.</source> (<year>2016</year>) <volume>35</volume>:<fpage>7</fpage>&#x02013;<lpage>12</lpage>. <pub-id pub-id-type="doi">10.1097/INF.0000000000000914</pub-id><?supplied-pmid 26372452?><pub-id pub-id-type="pmid">26372452</pub-id></mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Makino</surname><given-names>N</given-names></name><name><surname>Nakamura</surname><given-names>Y</given-names></name><name><surname>Yashiro</surname><given-names>M</given-names></name><name><surname>Ae</surname><given-names>R</given-names></name><name><surname>Tsuboi</surname><given-names>S</given-names></name><name><surname>Aoyama</surname><given-names>Y</given-names></name><etal/></person-group>. <article-title>Descriptive epidemiology of Kawasaki disease in Japan, 2011&#x02013;2012: from the results of the 22nd nationwide survey</article-title>. <source>J Epidemiol</source>. (<year>2015</year>) <volume>25</volume>:<fpage>239</fpage>&#x02013;<lpage>45</lpage>. <pub-id pub-id-type="doi">10.2188/jea.JE20140089</pub-id><?supplied-pmid 25716368?><pub-id pub-id-type="pmid">25716368</pub-id></mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Furusho</surname><given-names>K</given-names></name><name><surname>Kamiya</surname><given-names>T</given-names></name><name><surname>Nakano</surname><given-names>H</given-names></name><name><surname>Kiyosawa</surname><given-names>N</given-names></name><name><surname>Shinomiya</surname><given-names>K</given-names></name><name><surname>Hayashidera</surname><given-names>T</given-names></name><etal/></person-group>. <article-title>High-dose intravenous gammaglobulin for Kawasaki disease</article-title>. <source>Lancet</source>. (<year>1984</year>) <volume>2</volume>:<fpage>1055</fpage>&#x02013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1016/s0140-6736(84)91504-6</pub-id><?supplied-pmid 7671129?><pub-id pub-id-type="pmid">6209513</pub-id></mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Orenstein</surname><given-names>JM</given-names></name><name><surname>Shulman</surname><given-names>ST</given-names></name><name><surname>Fox</surname><given-names>LM</given-names></name><name><surname>Baker</surname><given-names>SC</given-names></name><name><surname>Takahashi</surname><given-names>M</given-names></name><name><surname>Bhatti</surname><given-names>TR</given-names></name><etal/></person-group>. <article-title>Three linked vasculopathic processes characterize Kawasaki disease: a light and transmission electron microscopic study</article-title>. <source>PLoS ONE</source>. (<year>2012</year>) <volume>7</volume>:<fpage>e38998</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0038998</pub-id><?supplied-pmid 22723916?><pub-id pub-id-type="pmid">22723916</pub-id></mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takahashi</surname><given-names>K</given-names></name><name><surname>Oharaseki</surname><given-names>T</given-names></name><name><surname>Naoe</surname><given-names>S</given-names></name><name><surname>Wakayama</surname><given-names>M</given-names></name><name><surname>Yokouchi</surname><given-names>Y</given-names></name></person-group>. <article-title>Neutrophilic involvement in the damage to coronary arteries in acute stage of Kawasaki disease</article-title>. <source>Pediatr Int.</source> (<year>2005</year>) <volume>47</volume>:<fpage>305</fpage>&#x02013;<lpage>10</lpage>. <pub-id pub-id-type="doi">10.1111/j.1442-200x.2005.02049.x</pub-id><?supplied-pmid 15910456?><pub-id pub-id-type="pmid">15910456</pub-id></mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Springer</surname><given-names>TA</given-names></name></person-group>. <article-title>Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm</article-title>. <source>Cell</source>. (<year>1994</year>) <volume>76</volume>:<fpage>301</fpage>&#x02013;<lpage>14</lpage>. <pub-id pub-id-type="doi">10.1016/0092-8674(94)90337-9</pub-id><?supplied-pmid 7507411?><pub-id pub-id-type="pmid">7507411</pub-id></mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ley</surname><given-names>K</given-names></name><name><surname>Allietta</surname><given-names>M</given-names></name><name><surname>Bullard</surname><given-names>DC</given-names></name><name><surname>Morgan</surname><given-names>S</given-names></name></person-group>. <article-title>Importance of E-selectin for firm leukocyte adhesion <italic>in vivo</italic></article-title>. <source>Circ Res</source>. (<year>1998</year>) <volume>83</volume>:<fpage>287</fpage>&#x02013;<lpage>94</lpage>. <pub-id pub-id-type="doi">10.1161/01.res.83.3.287</pub-id><?supplied-pmid 9710121?><pub-id pub-id-type="pmid">9710121</pub-id></mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yao</surname><given-names>L</given-names></name><name><surname>Setiadi</surname><given-names>H</given-names></name><name><surname>Xia</surname><given-names>L</given-names></name><name><surname>Laszik</surname><given-names>Z</given-names></name><name><surname>Taylor</surname><given-names>FB</given-names></name><name><surname>McEver</surname><given-names>RP</given-names></name></person-group>. <article-title>Divergent inducible expression of P-selectin and E-selectin in mice and primates</article-title>. <source>Blood</source>. (<year>1999</year>) <volume>94</volume>:<fpage>3820</fpage>&#x02013;<lpage>8</lpage>. <?supplied-pmid 10572097?><pub-id pub-id-type="pmid">10572097</pub-id></mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wikaningrum</surname><given-names>R</given-names></name><name><surname>Highton</surname><given-names>J</given-names></name><name><surname>Parker</surname><given-names>A</given-names></name><name><surname>Coleman</surname><given-names>M</given-names></name><name><surname>Hessian</surname><given-names>PA</given-names></name><name><surname>Roberts-Thompson</surname><given-names>PJ</given-names></name><etal/></person-group>. <article-title>Pathogenic mechanisms in the rheumatoid nodule: comparison of proinflammatory cytokine production and cell adhesion molecule expression in rheumatoid nodules and synovial membranes from the same patient</article-title>. <source>Arthritis and Rheum</source>. (<year>1998</year>) <volume>41</volume>:<fpage>1783</fpage>&#x02013;<lpage>97</lpage>. <pub-id pub-id-type="doi">10.1002/1529-0131(199810)41:10&#x0003c;1783::AID-ART10&#x0003e;3.0.CO;2-W</pub-id><?supplied-pmid 9778219?><pub-id pub-id-type="pmid">9778219</pub-id></mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dutta</surname><given-names>P</given-names></name><name><surname>Hoyer</surname><given-names>FF</given-names></name><name><surname>Sun</surname><given-names>Y</given-names></name><name><surname>Iwamoto</surname><given-names>Y</given-names></name><name><surname>Tricot</surname><given-names>B</given-names></name><name><surname>Weissleder</surname><given-names>R</given-names></name><etal/></person-group>. <article-title>E-selectin inhibition mitigates splenic HSC activation and myelopoiesis in hypercholesterolemic mice with myocardial infarction</article-title>. <source>Arterioscler Thromb Vasc Biol</source>. (<year>2016</year>) <volume>36</volume>:<fpage>1802</fpage>&#x02013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1161/ATVBAHA.116.307519</pub-id><?supplied-pmid 27470513?><pub-id pub-id-type="pmid">27470513</pub-id></mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ko</surname><given-names>TM</given-names></name><name><surname>Kuo</surname><given-names>HC</given-names></name><name><surname>Chang</surname><given-names>JS</given-names></name><name><surname>Chen</surname><given-names>SP</given-names></name><name><surname>Liu</surname><given-names>YM</given-names></name><name><surname>Chen</surname><given-names>HW</given-names></name><etal/></person-group>. <article-title>CXCL10/IP-10 is a biomarker and mediator for Kawasaki disease</article-title>. <source>Circ Res</source>. (<year>2015</year>) <volume>116</volume>:<fpage>876</fpage>&#x02013;<lpage>83</lpage>. <pub-id pub-id-type="doi">10.1161/CIRCRESAHA.116.305834</pub-id><?supplied-pmid 25605650?><pub-id pub-id-type="pmid">25605650</pub-id></mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miura</surname><given-names>M</given-names></name><name><surname>Garcia</surname><given-names>FL</given-names></name><name><surname>Crawford</surname><given-names>SE</given-names></name><name><surname>Rowley</surname><given-names>AH</given-names></name></person-group>. <article-title>Cell adhesion molecule expression in coronary artery aneurysms in acute Kawasaki disease</article-title>. <source>Pediatr Infect Dis J</source>. (<year>2004</year>) <volume>23</volume>:<fpage>931</fpage>&#x02013;<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1097/01.inf.0000142171.91235.fc</pub-id><?supplied-pmid 15602193?><pub-id pub-id-type="pmid">15602193</pub-id></mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ren</surname><given-names>L</given-names></name><name><surname>Han</surname><given-names>F</given-names></name><name><surname>Xuan</surname><given-names>L</given-names></name><name><surname>Lv</surname><given-names>Y</given-names></name><name><surname>Gong</surname><given-names>L</given-names></name><name><surname>Yan</surname><given-names>Y</given-names></name><etal/></person-group>. <article-title>Clusterin ameliorates endothelial dysfunction in diabetes by suppressing mitochondrial fragmentation</article-title>. <source>Free Rad Biol Med</source>. (<year>2019</year>) <volume>145</volume>:<fpage>357</fpage>&#x02013;<lpage>73</lpage>. <pub-id pub-id-type="doi">10.1016/j.freeradbiomed.2019.10.008</pub-id><?supplied-pmid 31614179?><pub-id pub-id-type="pmid">31614179</pub-id></mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leeuwenberg</surname><given-names>JF</given-names></name><name><surname>Smeets</surname><given-names>EF</given-names></name><name><surname>Neefjes</surname><given-names>JJ</given-names></name><name><surname>Shaffer</surname><given-names>MA</given-names></name><name><surname>Cinek</surname><given-names>T</given-names></name><name><surname>Jeunhomme</surname><given-names>TM</given-names></name><etal/></person-group>. <article-title>E-selectin and intercellular adhesion molecule-1 are released by activated human endothelial cells <italic>in vitro</italic></article-title>. <source>Immunology</source>. (<year>1992</year>) <volume>77</volume>:<fpage>543</fpage>&#x02013;<lpage>9</lpage>. <?supplied-pmid 1283598?><pub-id pub-id-type="pmid">1283598</pub-id></mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qiu</surname><given-names>S</given-names></name><name><surname>Cai</surname><given-names>X</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Yang</surname><given-names>B</given-names></name><name><surname>Z&#x000fc;gel</surname><given-names>M</given-names></name><name><surname>Steinacker</surname><given-names>JM</given-names></name><etal/></person-group>. <article-title>Association between circulating cell adhesion molecules and risk of type 2 diabetes: a meta-analysis</article-title>. <source>Atherosclerosis</source>. (<year>2019</year>) <volume>287</volume>:<fpage>147</fpage>&#x02013;<lpage>54</lpage>. <pub-id pub-id-type="doi">10.1016/j.atherosclerosis.2019.06.908</pub-id><?supplied-pmid 31280040?><pub-id pub-id-type="pmid">31280040</pub-id></mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ma</surname><given-names>S</given-names></name><name><surname>Tian</surname><given-names>XY</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Mu</surname><given-names>C</given-names></name><name><surname>Shen</surname><given-names>H</given-names></name><name><surname>Bismuth</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>E-selectin-targeting delivery of microRNAs by microparticles ameliorates endothelial inflammation and atherosclerosis</article-title>. <source>Sci Rep</source>. (<year>2016</year>) <volume>6</volume>:<fpage>22910</fpage>. <pub-id pub-id-type="doi">10.1038/srep22910</pub-id>. <?supplied-pmid 26956647?><pub-id pub-id-type="pmid">26956647</pub-id></mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roth Flach</surname><given-names>RJ</given-names></name><name><surname>Matevossian</surname><given-names>A</given-names></name><name><surname>Akie</surname><given-names>TE</given-names></name><name><surname>Negrin</surname><given-names>KA</given-names></name><name><surname>Paul</surname><given-names>MT</given-names></name><name><surname>Czech</surname><given-names>MP</given-names></name></person-group>. <article-title>&#x003b2;3-Adrenergic receptor stimulation induces E-selectin-mediated adipose tissue inflammation</article-title>. <source>J Biol Chem</source>. (<year>2013</year>) <volume>288</volume>:<fpage>2882</fpage>&#x02013;<lpage>92</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M112.412346</pub-id><?supplied-pmid 23235150?><pub-id pub-id-type="pmid">23235150</pub-id></mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>von Asmuth</surname><given-names>EJ</given-names></name><name><surname>Smeets</surname><given-names>EF</given-names></name><name><surname>Ginsel</surname><given-names>LA</given-names></name><name><surname>Onderwater</surname><given-names>JJ</given-names></name><name><surname>Leeuwenberg</surname><given-names>JF</given-names></name><name><surname>Buurman</surname><given-names>WA</given-names></name></person-group>. <article-title>Evidence for endocytosis of E-selectin in human endothelial cells</article-title>. <source>Eur J Immunol</source>. (<year>1992</year>) <volume>22</volume>:<fpage>2519</fpage>&#x02013;<lpage>26</lpage>. <pub-id pub-id-type="doi">10.1002/eji.1830221009</pub-id><?supplied-pmid 1382989?><pub-id pub-id-type="pmid">1382989</pub-id></mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>West</surname><given-names>AP</given-names></name><name><surname>Shadel</surname><given-names>GS</given-names></name><name><surname>Ghosh</surname><given-names>S</given-names></name></person-group>. <article-title>Mitochondria in innate immune responses</article-title>. <source>Nat Rev Immunol</source>. (<year>2011</year>) <volume>11</volume>:<fpage>389</fpage>&#x02013;<lpage>402</lpage>. <pub-id pub-id-type="doi">10.1038/nri2975</pub-id><pub-id pub-id-type="pmid">21597473</pub-id></mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rowley</surname><given-names>AH</given-names></name><name><surname>Wylie</surname><given-names>KM</given-names></name><name><surname>Kim</surname><given-names>KY</given-names></name><name><surname>Pink</surname><given-names>AJ</given-names></name><name><surname>Yang</surname><given-names>A</given-names></name><name><surname>Reindel</surname><given-names>R</given-names></name><etal/></person-group>. <article-title>The transcriptional profile of coronary arteritis in Kawasaki disease</article-title>. <source>BMC Genomics</source>. (<year>2015</year>) <volume>16</volume>:<fpage>1076</fpage>. <pub-id pub-id-type="doi">10.1186/s12864-015-2323-5</pub-id><?supplied-pmid 26679344?><pub-id pub-id-type="pmid">26679344</pub-id></mixed-citation></ref><ref id="B28"><label>28.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sotty</surname><given-names>J</given-names></name><name><surname>Kluza</surname><given-names>J</given-names></name><name><surname>De Sousa</surname><given-names>C</given-names></name><name><surname>Tardivel</surname><given-names>M</given-names></name><name><surname>Anth&#x000e9;rieu</surname><given-names>S</given-names></name><name><surname>Alleman</surname><given-names>LY</given-names></name><etal/></person-group>. <article-title>Mitochondrial alterations triggered by repeated exposure to fine (PM2.5-0.18) and quasi-ultrafine (PM0.18) fractions of ambient particulate matter</article-title>. <source>Environ Int.</source> (<year>2020</year>) <volume>142</volume>:<fpage>105830</fpage>. <pub-id pub-id-type="doi">10.1016/j.envint.2020.105830</pub-id><?supplied-pmid 32585499?><pub-id pub-id-type="pmid">32585499</pub-id></mixed-citation></ref><ref id="B29"><label>29.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Quintero</surname><given-names>M</given-names></name><name><surname>Colombo</surname><given-names>SL</given-names></name><name><surname>Godfrey</surname><given-names>A</given-names></name><name><surname>Moncada</surname><given-names>S</given-names></name></person-group>. <article-title>Mitochondria as signaling organelles in the vascular endothelium</article-title>. <source>Proc Natl Acad Sci USA</source>. (<year>2006</year>) <volume>103</volume>:<fpage>5379</fpage>&#x02013;<lpage>84</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.0601026103</pub-id><?supplied-pmid 16565215?><pub-id pub-id-type="pmid">16565215</pub-id></mixed-citation></ref><ref id="B30"><label>30.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Culic</surname><given-names>O</given-names></name><name><surname>Gruwel</surname><given-names>ML</given-names></name><name><surname>Schrader</surname><given-names>J</given-names></name></person-group>. <article-title>Energy turnover of vascular endothelial cells</article-title>. <source>Am J Physiol</source>. (<year>1997</year>) <volume>273</volume>:<fpage>C205</fpage>&#x02013;<lpage>13</lpage>. <pub-id pub-id-type="doi">10.1152/ajpcell.1997.273.1.C205</pub-id><?supplied-pmid 9252458?><pub-id pub-id-type="pmid">9252458</pub-id></mixed-citation></ref><ref id="B31"><label>31.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Davidson</surname><given-names>SM</given-names></name><name><surname>Duchen</surname><given-names>MR</given-names></name></person-group>. <article-title>Endothelial mitochondria: contributing to vascular function and disease</article-title>. <source>Circ Res</source>. (<year>2007</year>) <volume>100</volume>:<fpage>1128</fpage>&#x02013;<lpage>41</lpage>. <pub-id pub-id-type="doi">10.1161/01.RES.0000261970.18328.1d</pub-id><?supplied-pmid 17463328?><pub-id pub-id-type="pmid">17463328</pub-id></mixed-citation></ref><ref id="B32"><label>32.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shadel</surname><given-names>GS</given-names></name><name><surname>Horvath</surname><given-names>TL</given-names></name></person-group>. <article-title>Mitochondrial ROS signaling in organismal homeostasis</article-title>. <source>Cell</source>. (<year>2015</year>) <volume>163</volume>:<fpage>560</fpage>&#x02013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2015.10.001</pub-id><?supplied-pmid 26496603?><pub-id pub-id-type="pmid">26496603</pub-id></mixed-citation></ref><ref id="B33"><label>33.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wood</surname><given-names>PG</given-names></name><name><surname>Gillespie</surname><given-names>JI</given-names></name></person-group>. <article-title>Evidence for mitochondrial Ca(2+)-induced Ca<sup>2+</sup> release in permeabilised endothelial cells</article-title>. <source>Biochem Biophys Res Commun</source>. (<year>1998</year>) <volume>246</volume>:<fpage>543</fpage>&#x02013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1006/bbrc.1998.8661</pub-id><?supplied-pmid 9610399?><pub-id pub-id-type="pmid">9610399</pub-id></mixed-citation></ref><ref id="B34"><label>34.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yoshida</surname><given-names>LS</given-names></name><name><surname>Tsunawaki</surname><given-names>S</given-names></name></person-group>. <article-title>Expression of NADPH oxidases and enhanced H(2)O(2)-generating activity in human coronary artery endothelial cells upon induction with tumor necrosis factor-alpha</article-title>. <source>Int Immunopharmacol</source>. (<year>2008</year>) <volume>8</volume>:<fpage>1377</fpage>&#x02013;<lpage>85</lpage>. <pub-id pub-id-type="doi">10.1016/j.intimp.2008.05.004</pub-id><?supplied-pmid 18687299?><pub-id pub-id-type="pmid">18687299</pub-id></mixed-citation></ref><ref id="B35"><label>35.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Romaschenko</surname><given-names>VP</given-names></name><name><surname>Zinovkin</surname><given-names>RA</given-names></name><name><surname>Galkin</surname><given-names>II</given-names></name><name><surname>Zakharova</surname><given-names>VV</given-names></name><name><surname>Panteleeva</surname><given-names>AA</given-names></name><name><surname>Tokarchuk</surname><given-names>AV</given-names></name><etal/></person-group>. <article-title>Low concentrations of uncouplers of oxidative phosphorylation prevent inflammatory activation of endothelial cells by tumor necrosis factor</article-title>. <source>Biochem Biokhim</source>. (<year>2015</year>) <volume>80</volume>:<fpage>610</fpage>&#x02013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1134/S0006297915050144</pub-id><?supplied-pmid 26071781?><pub-id pub-id-type="pmid">26071781</pub-id></mixed-citation></ref><ref id="B36"><label>36.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Collins</surname><given-names>T</given-names></name><name><surname>Read</surname><given-names>MA</given-names></name><name><surname>Neish</surname><given-names>AS</given-names></name><name><surname>Whitley</surname><given-names>MZ</given-names></name><name><surname>Thanos</surname><given-names>D</given-names></name><name><surname>Maniatis</surname><given-names>T</given-names></name></person-group>. <article-title>Transcriptional regulation of endothelial cell adhesion molecules: NF-kappa B and cytokine-inducible enhancers</article-title>. <source>FASEB J</source>. (<year>1995</year>) <volume>9</volume>:<fpage>899</fpage>&#x02013;<lpage>909</lpage>. <?supplied-pmid 7542214?><pub-id pub-id-type="pmid">7542214</pub-id></mixed-citation></ref><ref id="B37"><label>37.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zakharova</surname><given-names>VV</given-names></name><name><surname>Pletjushkina</surname><given-names>OY</given-names></name><name><surname>Galkin</surname><given-names>II</given-names></name><name><surname>Zinovkin</surname><given-names>RA</given-names></name><name><surname>Chernyak</surname><given-names>BV</given-names></name><name><surname>Krysko</surname><given-names>DV</given-names></name><etal/></person-group>. <article-title>Low concentration of uncouplers of oxidative phosphorylation decreases the TNF-induced endothelial permeability and lethality in mice</article-title>. <source>Biochim Biophys Acta</source>. (<year>2017</year>) <volume>1863</volume>:<fpage>968</fpage>&#x02013;<lpage>77</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbadis.2017.01.024</pub-id><?supplied-pmid 28131916?><pub-id pub-id-type="pmid">28131916</pub-id></mixed-citation></ref><ref id="B38"><label>38.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ichiyama</surname><given-names>T</given-names></name><name><surname>Ueno</surname><given-names>Y</given-names></name><name><surname>Isumi</surname><given-names>H</given-names></name><name><surname>Niimi</surname><given-names>A</given-names></name><name><surname>Matsubara</surname><given-names>T</given-names></name><name><surname>Furukawa</surname><given-names>S</given-names></name></person-group>. <article-title>An immunoglobulin agent (IVIG) inhibits NF-kappaB activation in cultured endothelial cells of coronary arteries <italic>in vitro</italic></article-title>. <source>Inflammation</source>. (<year>2004</year>) <volume>53</volume>:<fpage>253</fpage>&#x02013;<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1007/s00011-004-1255-3</pub-id><?supplied-pmid 15167972?><pub-id pub-id-type="pmid">15167972</pub-id></mixed-citation></ref></ref-list></back></article>